指南与共识技术与安全

2025 WRIB白皮书:生物标志物分析、LBA/CBA与法规建议

2025 White Paper on Recent Issues in Bioanalysis: Biomarkers Calibrators & Stability; Evaluation of NULISA; Neurofilament & Autoantibody Biomarker Assays; Removing IgM Interference; ELISpot & FluoroSpot Best Practices; Modular HD Cytometry; Single-cell Analysis Imaging Cytometry (PART 2A - Recommendations on Biomarkers Discovery, Development, Validation & Regulatory Approval, Ligand-Binding Assays
指南 / 共识 · Bioanalysis · 2026-01-29

第19届WRIB于2025年4月在美国新奥尔良召开,超过1200名来自药企、CRO及监管机构的专家参与。本白皮书为研讨会第二部分,涵盖生物标志物发现、开发、验证与监管批准建议,以及配体结合分析、细胞分析、IVD/CDx和生物标志物分析验证的法规意见。

要点

  • 本白皮书聚焦生物标志物分析方法验证和法规要求,不涉及具体影像诊断阈值。
  • 内容适用于涉及生物标志物定量或伴随诊断的影像研究设计参考。
  • 放射科/超声科日常阅片无需直接应用其中实验方法学条款。

核心结论

  • 本白皮书汇总了2025年WRIB关于生物标志物分析、配体结合分析、细胞分析及法规监管的讨论建议。
  • 该文件不提供可直接用于放射或超声影像诊断的阈值、敏感度或特异度数据。

研究设计与样本

  • 由2025年第19届WRIB研讨会专家组讨论形成,参会人数超过1200人。
  • 参与者涵盖制药、生物技术公司、CRO及多个监管机构。
  • 会议包括3个主研讨会和7个专题研讨会,按原描述跨度为1周。
  • 内容涉及生物标志物、免疫原性、基因治疗、细胞治疗及疫苗的生物分析问题。

诊断标准与关键数值

  • 白皮书涵盖生物标志物发现、开发、验证与监管批准的推荐意见。
  • 涉及配体结合分析、细胞分析、IVD/CDx及生物标志物分析验证。
  • 原文未提供与放射科或超声科相关的具体诊断标准或影像分级系统。

临床应用与阅片要点

  • 影像相关研究中若使用生物标志物定量或伴随诊断方法,可参考本白皮书的验证框架。
  • 放射科/超声科在日常阅片与报告中无需直接应用该白皮书中的实验室方法建议。

局限性

  • 本白皮书面向生物分析实验室与药企,不针对医学影像或超声诊断场景。
  • 内容主要为共识建议,未报告传统意义的样本量、参考标准或影像技术平台。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

The 19th Workshop on Recent Issues in Bioanalysis (19th WRIB) took place in New Orleans, LA, USA on April 7-11, 2025. Over 1200 professionals representing pharma/biotech companies, CROs, and multiple regulatory agencies convened to actively discuss the most current topics of interest in bioanalysis. The 19th WRIB included 3 Main Workshops and 7 Specialized Workshops that together spanned 1 week to allow an exhaustive and thorough coverage of all major issues in bioanalysis of biomarkers, immunogenicity, gene therapy, cell therapy and vaccines.Moreover, in-depth workshops on "Implementation Practice for the Newest ELN/LIMS Systems" and on "Vaccine Cell-Based/Functional & Molecular Assays as part of the harmonization of vaccine clinical assays global initiative" were the special features of the 19th edition.As in previous years, WRIB continued to gather a wide diversity of international, industry opinion leaders and Regulatory Agency experts working on both small and large molecules as well as gene, cell therapies and vaccines to facilitate sharing and discussions focused on improving quality, increasing regulatory compliance, and achieving scientific excellence on bioanalytical issues.This 2025 White Paper encompasses recommendations emerging from the extensive discussions held during the workshop and is aimed to provide the bioanalytical community with key information and practical solutions on topics and issues addressed, in an effort to enable advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2025 edition of this comprehensive White Paper has been divided into three parts for editorial reasons.This publication (Part 2) covers in the Part 2A the recommendations on Biomarkers/BAV, IVD/CDx, Ligand-Binding Assays and Cell-Based Assays and in Part 3B the Regulatory Inputs on these topics. Part 1 (Mass Spectrometry Assays and Regulated Bioanalysis/BMV) and Part 3 (Gene Therapy, Cell therapy, Vaccines and Biotherapeutics Immunogenicity) are published in volume 18 of Bioanalysis, issues 3 and 1 (2026), respectively.

来源:Bioanalysis,查看原文。版权归原作者所有。

引用

  1. Hersey, McGuire, Kholmanskikh, et al. 2025 White Paper on Recent Issues in Bioanalysis: Biomarkers Calibrators & Stability; Evaluation of NULISA; Neurofilament & Autoantibody Biomarker Assays; Removing IgM Interference; ELISpot & FluoroSpot Best Practices; Modular HD Cytometry; Single-cell Analysis Imaging Cytometry (PART 2A - Recommendations on Biomarkers Discovery, Development, Validation & Regulatory Approval, Ligand-Binding Assays (LBA) and Cell-Based Assays (CBA) PART 2B - Regulatory Agencies' Input on Biomarkers, IVD/CDx and Biomarker Assay Validation (BAV)). Bioanalysis. 2026. PMID: 41609129. doi:10.1080/17576180.2025.2599698

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。